Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nkarta, Inc.

Get SEC filing alerts via email and in your feed for Nkarta, Inc.

NKTX

Nkarta, Inc.

About Nkarta, Inc.

Nkarta, Inc. develops allogeneic, off-the-shelf natural killer (NK) cell therapies targeting autoimmune diseases and cancers. Its proprietary platform engineers NK cells with enhanced recognition, persistence, and cryopreservation capabilities. The company’s lead candidate, NKX019, targets CD19-positive B cells to treat autoimmune conditions like lupus and scleroderma. Focused on scalable manufacturing and innovative cell engineering, Nkarta aims to provide broadly accessible, disease-modifying immunotherapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Nkarta, Inc.

1
1
Nkarta, Inc. Nkarta Reports Q1 2026 Financial Results with $27.8 Million Net Loss

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Nkarta, Inc. Nkarta Reports $104.1 Million Net Loss for 2025, Focuses on NKX019 Development

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Nkarta, Inc. Nkarta Reports Q3 2025 Financial Results with Reduced Net Loss of $21.7 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Nkarta, Inc. Nkarta Reports Q2 2025 Financial Results with Reduced Net Loss and Increased Cash Reserves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Nkarta, Inc. Nkarta Reports $31.98 Million Net Loss in Q1 2025, Faces Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Nkarta, Inc. Nkarta Reports $108.79 Million Net Loss for 2024, Highlights Clinical Trial Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Nkarta, Inc. Nkarta, Inc. Reports Financial Results for Q3 2024, Announces Restructuring and Focus on Lead Product Candidate

Via official filing (AI summary) | over 1 year ago | 0 comments